{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:39Z","timestamp":1793745339220,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41591-026-04538-9","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:01:53Z","timestamp":1783587713000},"page":"3294-3301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b\/2 trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Jiujie","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-3115","authenticated-orcid":false,"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"4538_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"4538_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa, T., Wood, L. D., Itoi, T. & Takaori, K. Pancreatic cancer. Lancet 388, 73\u201385 (2016).","journal-title":"Lancet"},{"key":"4538_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851\u2013862 (2021).","journal-title":"JAMA"},{"key":"4538_CR4","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008\u20132020 (2020).","journal-title":"Lancet"},{"key":"4538_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 19, 439\u2013457 (2021).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"4538_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4538_CR7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395\u20132406 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4538_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","volume":"10","author":"P Dey","year":"2020","unstructured":"Dey, P. et al. Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment. Cancer Discov. 10, 608\u2013625 (2020).","journal-title":"Cancer Discov."},{"key":"4538_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"4538_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656\u2013670 (2012).","journal-title":"Cell"},{"key":"4538_CR11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig, M. N., Ashwood, L. M., Kondrashova, O. & Sutherland, K. D. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer 9, 955\u2013967 (2023).","journal-title":"Trends Cancer"},{"key":"4538_CR12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 41, 1606\u20131620 (2023).","journal-title":"Cancer Cell"},{"key":"4538_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","volume":"32","author":"S Stickler","year":"2024","unstructured":"Stickler, S., Rath, B. & Hamilton, G. Targeting KRAS in pancreatic cancer. Oncol. Res. 32, 799\u2013805 (2024).","journal-title":"Oncol. Res."},{"key":"4538_CR14","doi-asserted-by":"publisher","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","volume":"8","author":"AM Waters","year":"2018","unstructured":"Waters, A. M. & Der, C. J. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb. Perspect. Med. 8, a031435 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"4538_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761\u2013774 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"4538_CR16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible?. Nat. Rev. Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4538_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102070","volume":"89","author":"D Uprety","year":"2020","unstructured":"Uprety, D. & Adjei, A. A. KRAS: from undruggable to a druggable cancer target. Cancer Treat. Rev. 89, 102070 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"4538_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JM Ostrem","year":"2016","unstructured":"Ostrem, J. M. & Shokat, K. M. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat. Rev. Drug Discov. 15, 771\u2013785 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4538_CR19","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell, J. B. et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J. Med. Chem. 63, 6679\u20136693 (2020).","journal-title":"J. Med. Chem."},{"key":"4538_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman, B. A. et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J. Med. Chem. 63, 52\u201365 (2020).","journal-title":"J. Med. Chem."},{"key":"4538_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33\u201343 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4538_CR22","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"4538_CR23","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"4538_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads0239","volume":"389","author":"C Weller","year":"2025","unstructured":"Weller, C. et al. A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. Science 389, eads0239 (2025).","journal-title":"Science"},{"key":"4538_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-021-00368-w","volume":"8","author":"Z Mao","year":"2022","unstructured":"Mao, Z. et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 8, 5 (2022).","journal-title":"Cell Discov."},{"key":"4538_CR26","doi-asserted-by":"publisher","first-page":"15823","DOI":"10.1073\/pnas.1904529116","volume":"116","author":"D Kessler","year":"2019","unstructured":"Kessler, D. et al. Drugging an undruggable pocket on KRAS. Proc. Natl Acad. Sci. USA 116, 15823\u201315829 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4538_CR27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou, C. et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRASG12D-mutant cancer. Cancer Cell 42, 1286\u20131300 (2024).","journal-title":"Cancer Cell"},{"key":"4538_CR28","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"4538_CR29","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1158\/0008-5472.CAN-24-1926","volume":"84","author":"AJ Aguirre","year":"2024","unstructured":"Aguirre, A. J., Stanger, B. Z. & Maitra, A. Hope on the horizon: a revolution in KRAS inhibition is creating a new treatment paradigm for patients with pancreatic cancer. Cancer Res. 84, 2950\u20132953 (2024).","journal-title":"Cancer Res."},{"key":"4538_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/OP.24.00279","volume":"21","author":"V Chung","year":"2025","unstructured":"Chung, V., Mizrahi, J. D. & Pant, S. Novel therapies for pancreatic cancer. JCO Oncol. Pract. 21, 613\u2013619 (2025).","journal-title":"JCO Oncol. Pract."},{"key":"4538_CR31","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"4538_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63718-2","volume":"16","author":"VS Kalluri","year":"2025","unstructured":"Kalluri, V. S. et al. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat. Commun. 16, 8696 (2025).","journal-title":"Nat. Commun."},{"key":"4538_CR33","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","volume":"42","author":"J Feng","year":"2023","unstructured":"Feng, J. et al. Feedback activation of EGFR\/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene 42, 1620\u20131633 (2023).","journal-title":"Oncogene"},{"key":"4538_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00637-4","volume":"14","author":"Y Li","year":"2025","unstructured":"Li, Y., Zhao, J. & Li, Y. New exploration of KRASG12D inhibitors and the mechanisms of resistance. Exp. Hematol. Oncol. 14, 39 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"4538_CR35","doi-asserted-by":"crossref","unstructured":"Spira, A. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. In Proc. 2025 ASCO Gastrointestinal Cancers Symposium, abstract 724 (American Society of Clinical Oncology, 2025).","DOI":"10.1200\/JCO.2025.43.4_suppl.724"},{"key":"4538_CR36","doi-asserted-by":"crossref","unstructured":"Park, W. et al. Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Ann. Oncol. 35, S486\u2013S487 (2024).","DOI":"10.1016\/j.annonc.2024.08.675"},{"key":"4538_CR37","doi-asserted-by":"crossref","unstructured":"Zhou, A. et al. Efficacy and safety of GFH375 monotherapy in previously treated advanced KRASG12D-mutant pancreatic ductal adenocarcinoma (PDAC). In ESMO Congress, LBA84 (European Society for Medical Oncology, 2025).","DOI":"10.1016\/j.annonc.2025.09.099"},{"key":"4538_CR38","doi-asserted-by":"crossref","unstructured":"Garrido-Laguna, I. et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). In Proc. 2025 ASCO Gastrointestinal Cancers Symposium, abstract 722 (American Society of Clinical Oncology, 2025).","DOI":"10.1200\/JCO.2025.43.4_suppl.722"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04538-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04538-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04538-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:02:31Z","timestamp":1789480951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04538-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4538"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04538-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.Y., X.L., Y.C., M.Z. and H.H. are employed by Jiangsu Hengrui Pharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}